Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most common solid tumor entities worldwide and the third leading cause of cancer related death. For advanced stage disease, systemic pharmacotherapy is the only established therapy, targeting the oncogene protein kinases pathways. However, chemotherapy still yields poor response rates and survival in those patients. Recently, it could be demonstrated, that activating the protein phosphatase pathways may have a therapeutic impact on various types of cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
